Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.

Cancer Immunol Immunother · 2023 · PMC10264535 · PMID 36823323

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Treatment with BEMPEG plus nivolumab showed a trend toward increased PFS for these KIR-ligand present TNBC patients ( p = 0.06) (Fig. 2 A) and significantly improved OR ( p = 0.009; 36.4 vs. 0%) and tumor shrinkage ( p = 0.02; median change −23.5 vs. +12.8%) as compared to their KIR-ligand missing counterparts (Fig. 2 B, C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.